Abstract:Background/Aims: Osteosarcoma is a common primary malignant bone tumor that mainly occurs in childhood and adolescence. Despite developments in the diagnosis and treatment of osteosarcoma, the prognosis is still very poor. Cinobufagin is an active component in the anti-tumor Chinese medicine called “Chan Su”, and we previously revealed that cinobufagin induced apoptosis and reduced the viability of osteosarcoma cells; however, the underlying mechanism remains to be elucidated. Herein, the present study was undertaken to illuminate the molecular mechanism of cinobufagin-induced apoptosis of osteosarcoma cell. Methods: U2OS and 143B cells were treated with different concentrations of cinobufagin. Cell viability, colony formation ability and morphological changes were assessed by a CCK-8 assay, a clonogenic assay and light microscopy, respectively. Cell apoptosis was detected by Hoechst 33258 and Annexin V-FITC/PI staining. Reactive oxygen species (ROS) and mitochondrial membrane potential (ΔΨm) were determined by flow cytometry. Glutathione (GSH) levels were detected by a GSH and GSSG assay kit. The levels of apoptosis-related proteins were determined by western blotting, and 143B cells were introduced to establish a xenograft tumor model. The effect of cinobufagin on osteosarcoma was further investigated in vivo. Results: Our results showed that cinobufagin significantly reduced the viability of U2OS and 143B cells in vitro in a dose-and time-dependent manner. In addition, cinobufagin-induced apoptosis in U2OS and 143B cells was concentration-dependent. Moreover, we found that cinobufagin treatment increased the level of intracellular ROS, decreased ΔΨm, reduced GSH and inhibited GSH reductase (GR). The effects of cinobufagin on cell proliferation, apoptosis, ROS generation and ΔΨm loss were dramatically reversed when the cells were pretreated with the thiol-antioxidants NAC or GSH. Moreover, cinobufagin treatment increased the expression of the pro-apoptotic protein Bax and decreased the expression of the anti-apoptitic protein Bcl-2, thus altering the ratio of Bax to Bcl-2. Furthermore, Cinobufagin treatment caused cytochrome c release from the mitochondria to cytoplasm, thus increasing the protein levels of cleaved-caspase family members to induce apoptosis. Ac-DEVD-CHO or Z-LEHD-FMK significantly reduced cinobufagin-induced apoptosis. Finally, a subcutaneous xenograft animal study verified that cinobufagin also significantly suppressed osteosarcoma growth in vivo. Conclusions: Our present data demonstrated that cinobufagin triggered cell apoptosis in osteosarcoma cells via the intrinsic mitochondria-dependent apoptosis pathway by the accumulation of ROS and the loss of ΔΨm. In an in vivo subcutaneous xenograft model, cinobufagin exhibited excellent tumor inhibitory effects. These results suggest that cinobufagin might potentially be further developed as an anti-tumor candidate for treating osteosarcoma patients in the clinic.

[The Research on the Anti-glioma Effect and Mechanism of Cinobufagin].

Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells.

Effect of Cinobufagin on Proliferation and Apoptosis of U2OS

Effect of Cinobufacini on MDA-MB-231 Cells Proliferation,Migration and Apoptosis

Study on Apoptosis of NB4 Cells Induced by Cinobufagin and Its Mechanism

Cinobufagin is a Selective Anti-Cancer Agent Against Tumors with EGFR Amplification and PTEN Deletion

Cinobufagin-induced apoptosis in osteosarcoma cells in vitro

Effect of Celastrus orbiculatus Extract on Cell Proliferation and Apoptosis of U251 Cells and Its Molecular Mechanism

Effect of cinobufacini on the biological characteristics of MDA-MB-231 breast cancer cell line

Cinobufagin Inhibits Tumor Growth by Inducing Apoptosis Through Notch Signaling Pathways in Human Cholangiocarcinoma

Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.

Cinobufacini Induced MDA-MB-231 Cell Apoptosis-Associated Cell Cycle Arrest and Cytoskeleton Function.

The effect of cinobufacin combined with gemcitabine on the proliferation and osteopontin expression of HepG2 cells

Cucurbitacin B inhibits growth and induces apoptosis through the JAK2/STAT3 and MAPK pathways in SH‑SY5Y human neuroblastoma cells.

Inhibitory Effect of Cucurbitacin E on the Proliferation of Breast Cancer Cells and Its Mechanism

The Glycogen Synthase Kinase-3Β/nuclear Factor-Kappa B Pathway is Involved in Cinobufagin-Induced Apoptosis in Cultured Osteosarcoma Cells

Apoptosis-inducing Activity of Compounds Screened and Characterized from Cinobufacini by Bioassay-Guided Isolation.

Cinobufacini Induces the Apoptosis of U937 Cells and Its Mechanism

Cyclovirobuxine D Inhibits Cell Proliferation and Migration and Induces Apoptosis in Human Glioblastoma Multiforme and Low-Grade Glioma

Cinobufagin Induces Apoptosis in Osteosarcoma Cells Via the Mitochondria-Mediated Apoptotic Pathway

The Effects of Cinobufagin on Hepatocellular Carcinoma Cells Enhanced by MRT68921, an Autophagy Inhibitor